Press Release

MGEN $4.75 $ - 0.16 (3.26%)

miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018

Company Release - 7/25/2018 7:00 AM ET

BOULDER, Colo., July 25, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Tuesday, August 7, 2018, at 4:30 p.m. ET to discuss its financial results for the second quarter 2018.

Participants may access the call by dialing (800) 289-0438 in the U.S. or (323) 794-2423 outside the U.S. and providing the conference ID number: 2516510. The call will also be webcast and can be accessed from the Investors and Media section of the Company’s website at www.miragen.com.  A replay of this conference call will be available on miRagen’s website approximately one hour after the event.

About miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen (MRG-106), MRG-201, and MRG-110. miRagen’s clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers, as well as certain cells involved in inflammation. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being developed under a license and collaboration agreement with Servier for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety and manufacturability of the product candidate in preclinical studies. For more information, please visit www.miragen.com.

For information on clinical trials please visit www.clinicaltrials.gov.

Investor/Media Contact:                                                 
Adam Levy                                                 
Chief Business Officer                                                 
(720) 407-4595                                                 
alevy@miragen.com

Primary Logo

Source: Miragen Therapeutics, Inc.